Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Biseptine is a topical antiseptic solution widely used for skin disinfection and the treatment of minor wounds. It is a combination product containing three active ingredients: chlorhexidine digluconate, benzalkonium chloride, and benzyl alcohol. Chlorhexidine is a biguanide that provides long-lasting antibacterial activity by binding to and disrupting the bacterial cell wall and plasma membrane. Benzalkonium chloride, a quaternary ammonium compound, acts as a cationic surfactant that further destabilizes microbial membranes. Benzyl alcohol contributes to the antiseptic effect and provides mild local anesthetic properties. Together, these components offer broad-spectrum efficacy against Gram-positive and Gram-negative bacteria, as well as certain fungi and viruses. It is primarily marketed by Bayer and is a staple in first-aid and surgical skin preparation in several European markets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Biseptine.